An interventional study of Catheter Placement with Solopass System in Hydrocephalus, sponsored by Milton S. Hershey Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Hydrocephalus with a site in United States — 22 open to participants now, 26 under way, none of them phase 3. Hydrocephalus · United States.
Among the 77 studies in Hydrocephalus with a site in United States, this one is the 34th largest by planned enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 with no phase, reaches primary completion later than 10 of the 24 other live ones, and was the 60th registered.
190 studies on the registry are indexed under Hydrocephalus; 52 are open to participants now.
Browse Hydrocephalus studies →22 of the 77 studies in Hydrocephalus with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital of Philadelphia · Sites in United States
Ages 1 min–18 mo
Rhaeos, Inc. · Sites in United States
Rhaeos, Inc. · Sites in United States
Rhaeos, Inc. · Sites in United States
Ages 2+
Rhaeos, Inc. · Sites in United States
Ages 6–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Hydrocephalus studies recruiting now, 18 (58%) set no upper age limit and 6 (19%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 3 · Phase 4 3
First in 1985; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 41 across 97 interventional studies indexed under Hydrocephalus.
Median enrollment 33 across the 42 interventional studies, 66 across the 34 observational. Of the 41 that completed or were terminated, 8 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 77 have an industry lead sponsor. The 10 most frequent:
Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.
Milton S. Hershey Medical Center has 1 study filed under Hydrocephalus — fewer than ten, so there is no comparison to draw.
11 of the studies in Hydrocephalus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT07679035Rhaeos, Inc.Study of Shunt Flow Under Different Valve Settings Using a Wireless Sensor | 2026-11-30 |
| NCT02601339Boston Children's HospitalNIRS Monitoring in Premature Infants | 2026-12 |
| NCT06253858Milton S. Hershey Medical CenterUltrasound (US) Guided External Ventricular Catheter Placement | 2026-12-01 |
| NCT07478926Rhaeos, Inc.Flow Detection in Open and Closed Shunt Valve Periods | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 77 studies in Hydrocephalus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the accuracy the SOLOPASS® System US based in the placement of external ventricular drain into the cranial cavity. This study will aim at evaluating the proposed efficacy of the device in targeting the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Solopass US system will be used during catheter placement procedure to guide the placement of the catheter.
Device: Catheter Placement with Solopass System
This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
Average number of passes needed to place the catheter in each subject.
Measured by the number of passes needed to place the catheter. If the first attempt fails, another US sweep will be performed, and another attempt will be performed. If that fails, then the procedure will be aborted.
Time frame: 0 minutes
Post procedure imaging accuracy of the placement of the EVD will be performed by reviewing post procedure imaging using the Kakarla scoring system
Grade 1 means optimal placement in the ipsilateral frontal horn or third ventricle; Grade 2 means a functional placement in the contralateral lateral ventricle or no eloquent cortex; and Grade 3 means suboptimal placement in the eloquent cortex or nontarget cerebrospinal fluid space, with or without functional drainage
Time frame: up to 7 days
Length of time of the procedure
Number of minutes necessary to complete the procedure placement of the catheter
Time frame: Up to three hours
Number of revision
Quantity of revisions due to the catheter malfunction
Time frame: up to 7 days
Number of subjects with Cerebrospinal fluid (CSF) infection
CSF will be collected as part of standard of care after the procedure and tested for infection.
Time frame: up to 7 days
Number of subjects with Superficial surgical site infection (SSI)
(The CDC defines SSI as deep and superficial. A superficial incisional SSI is an infection in the area of the skin where the incision was made. A deep incisional SSI occurs beneath the incision area in the muscle and the tissues surrounding the muscles. Signs to be monitored daily and put in a checklist will include redness, pain, unexplained fever source, pain, warmth, pus or swelling.)
Time frame: up to 7 days
Longevity of the device function
Number of days until a subsequent catheter is placed
Time frame: up to 7 days
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 41 interventional studies with no phase under Hydrocephalus, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Milton S. Hershey Medical Center →